Cargando…

Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX

BACKGROUND: Korean National Health Insurance reimburses factor VIII (FVIII) and factor IX (FIX) clotting factor concentrate (CFC) infusions to discrepant activity levels, allowing elevation of FVIII activity to 60 IU/dL and FIX to 40 IU/dL. We aimed to assess hemostatic response to these target leve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Ki-Young, Jung, Soo-Young, Hwang, Sung-Ho, Lee, Su-Min, Park, Jong-Ho, Nam, Hyun-Ja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898993/ https://www.ncbi.nlm.nih.gov/pubmed/29662861 http://dx.doi.org/10.5045/br.2018.53.1.41

Ejemplares similares

Evaluation of Global Hemostatic Assays in Response to Factor VIII Inhibitors
por: Chen, Ping, et al.
Publicado: (2019)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Augmented Degradation of Factors VIII and IX in the Intermittent Movement State
por: Cohen, Haim, et al.
Publicado: (2023)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX
por: Wilmot, Helen V., et al.
Publicado: (2020)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

Maturation of coagulation factor IX during Xase formation as deduced using factor VIII‐derived peptides
por: Fang, Han, et al.
Publicado: (2019)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Prothrombin Time and Coagulation Factor IX as Hemostatic Risk Markers for Legg– Calvé–Perthes Disease
por: Hernández-Zamora, Edgar, et al.
Publicado: (2023)

Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report
por: Doma, Saša Anžej, et al.
Publicado: (2016)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Histones Induce the Procoagulant Phenotype of Endothelial Cells through Tissue Factor Up-Regulation and Thrombomodulin Down-Regulation
por: Kim, Ji Eun, et al.
Publicado: (2016)

Recurrent Cerebral Venous Thrombosis Associated with Elevated Factor VIII
por: Kim, Mi Jung, et al.
Publicado: (2006)

Lacerations to Zones VIII and IX: It Is Not Just a Tendon Injury
por: Fischer, Charla R., et al.
Publicado: (2011)

Further Data on the Stanford-Binet VIII- and IX-Year Tests
por: Wallin, J. E. Wallace
Publicado: (1933)

Molecular Analysis of Factor VIII and Factor IX Genes in Hemophilia Patients: Identification of Novel Mutations and Molecular Dynamics Studies
por: Al-Allaf, Faisal A., et al.
Publicado: (2017)

Effects of preanalytical frozen storage time and temperature on screening coagulation tests and factors VIII and IX activity
por: Zhao, Ying, et al.
Publicado: (2017)

PB2655: EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR
por: Koyun, Derya, et al.
Publicado: (2023)

Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism
por: Kilic, Nevin, et al.
Publicado: (2012)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review
por: Bosch, Alessandra, et al.
Publicado: (2023)

Discharged. Not Where to Lay His Head: Chapters VII, VIII, IX
por: Fleming, George
Publicado: (1886)

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
por: Robinson, Mary M., et al.
Publicado: (2021)

The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience
por: Bouyadmar, Meryem, et al.
Publicado: (2022)

MPs-ACT, an Assay to Evaluate the Procoagulant Activity of Microparticles
por: Gao, Yalong, et al.
Publicado: (2023)

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center
por: Yoo, Ki Young, et al.
Publicado: (2016)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations
por: Duarte, Rita Carolina Figueiredo, et al.
Publicado: (2017)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Monitoring of different factor VIII replacement products using a factor VIII one‐stage clotting assay on cobas t 511/711 analysers
por: Ketteler, Carolin, et al.
Publicado: (2021)

Acquired factor VIII deficiency after consuming the dried gallbladder of a cobra, Naja naja
por: Kim, Hyun Ju, et al.
Publicado: (2010)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Platelet Function and Factor VIII in Uremia(*)
por: Park, Hee Sook, et al.
Publicado: (1987)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
por: Naganawa, Hirokazu, et al.
Publicado: (2021)

Hemostatic Effect and Mechanism of Epidermal Growth Factor-Hemostatic Powder after Endoscopic Submucosal Dissection in a Porcine Model
por: Jung, Da Hyun, et al.
Publicado: (2023)

Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study
por: Kim, Soon Ki, et al.
Publicado: (2017)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Cannot write session to /tmp/vufind_sessions/sess_5an8cobpgi1fnf5n5l0htmeea4